Filtered By:
Drug: Medroxyprogesterone
This page shows you your search results in order of relevance. This is page number 18.
Order by Relevance | Date
Total 487 results found since Jan 2013.
Update to U.S. Selected Practice Recommendations for Contraceptive Use: Self-Administration of Subcutaneous Depot Medroxyprogesterone Acetate
MMWR Morb Mortal Wkly Rep. 2021 May 21;70(20):739-743. doi: 10.15585/mmwr.mm7020a2.ABSTRACTU.S. Selected Practice Recommendations for Contraceptive Use (U.S. SPR), adapted by CDC from global guidance developed by the World Health Organization (WHO), provides evidence-based guidance on contraceptive use for U.S. health care providers (1). During January-February, 2021, CDC evaluated the 2019 WHO recommendation on self-administered subcutaneous depot medroxyprogesterone acetate (DMPA-SC) (2). CDC adopted the WHO recommendation on the basis of moderate-certainty evidence that self-administered DMPA-SC is safe and effective, a...
Source: MMWR Morb Mortal Wkl... - May 20, 2021 Category: Epidemiology Authors: Kathryn M Curtis Antoinette Nguyen Jennifer A Reeves Elizabeth A Clark Suzanne G Folger Maura K Whiteman Source Type: research
Prescribing of long-acting reversible contraception by general practice registrars across different rural regions of australia: A cross-sectional analysis of the Registrar Clinical Encounters in Training Study data
CONCLUSIONS: Long-acting reversible contraception methods prescribed differ across different classifications of rurality. Women living in more rural/remote regions might have access difficulties for the levonorgestrel intrauterine device.PMID:34148268 | DOI:10.1111/ajr.12720
Source: The Australian Journal of Rural Health - June 20, 2021 Category: Rural Health Authors: Rachel Turner Amanda Tapley Sally Sweeney Andrew Davey Mieke van Driel Simon Morgan Neil Spike Kristen FitzGerald Parker Magin Source Type: research
A semi-mechanistic pharmacokinetic model for depot medroxyprogesterone acetate and drug-drug interactions with antiretroviral and antituberculosis treatment
Clin Pharmacol Ther. 2021 Jun 20. doi: 10.1002/cpt.2324. Online ahead of print.ABSTRACTDepot medroxyprogesterone acetate (DMPA) is an injectable hormonal contraceptive, widely used by women of childbearing potential living with HIV and/or tuberculosis. As medroxyprogesterone acetate (MPA) is a CYP3A4 substrate, drug-drug interactions (DDIs) with antiretroviral or antituberculosis treatment may lead to subtherapeutic MPA concentrations (<0.1 ng/mL), resulting in contraception failure, when DMPA is dosed at 12-week intervals. A pooled population pharmacokinetic analysis with 744 plasma MPA concentrations from 138 women tr...
Source: Clinical Pharmacology and Therapeutics - June 21, 2021 Category: Drugs & Pharmacology Authors: Jose Francis Rosie Mngqibisa Helen McIlleron Michelle A Kendall Xingye Wu Kelly E Dooley Cynthia Firnhaber Catherine Godfrey Susan E Cohn Paolo Denti A5093, A5283, A5338 study teams Source Type: research
Prescribing of long-acting reversible contraception by general practice registrars across different rural regions of australia: A cross-sectional analysis of the Registrar Clinical Encounters in Training Study data
CONCLUSIONS: Long-acting reversible contraception methods prescribed differ across different classifications of rurality. Women living in more rural/remote regions might have access difficulties for the levonorgestrel intrauterine device.PMID:34148268 | DOI:10.1111/ajr.12720
Source: The Australian Journal of Rural Health - June 20, 2021 Category: Rural Health Authors: Rachel Turner Amanda Tapley Sally Sweeney Andrew Davey Mieke van Driel Simon Morgan Neil Spike Kristen FitzGerald Parker Magin Source Type: research
A semi-mechanistic pharmacokinetic model for depot medroxyprogesterone acetate and drug-drug interactions with antiretroviral and antituberculosis treatment
Clin Pharmacol Ther. 2021 Jun 20. doi: 10.1002/cpt.2324. Online ahead of print.ABSTRACTDepot medroxyprogesterone acetate (DMPA) is an injectable hormonal contraceptive, widely used by women of childbearing potential living with HIV and/or tuberculosis. As medroxyprogesterone acetate (MPA) is a CYP3A4 substrate, drug-drug interactions (DDIs) with antiretroviral or antituberculosis treatment may lead to subtherapeutic MPA concentrations (<0.1 ng/mL), resulting in contraception failure, when DMPA is dosed at 12-week intervals. A pooled population pharmacokinetic analysis with 744 plasma MPA concentrations from 138 women tr...
Source: Clinical Pharmacology and Therapeutics - June 21, 2021 Category: Drugs & Pharmacology Authors: Jose Francis Rosie Mngqibisa Helen McIlleron Michelle A Kendall Xingye Wu Kelly E Dooley Cynthia Firnhaber Catherine Godfrey Susan E Cohn Paolo Denti A5093, A5283, A5338 study teams Source Type: research
Availability of inputs for reproductive planning in three cycles of the Program for Improvement of Access and Quality in Basic Healthcare: 2012, 2014, and 2018
The objective was to assess the availability of inputs for reproductive planning in basic healthcare units (UBS in Portuguese) that participated in the National Program for Improvement of Access and Quality of Basic Care (PMAQ-AB) and their distribution according to contextual factors. A comparative study was conducted of the three cycles of the PMAQ-AB (2012, 2014, and 2018). The study assessed the availability in the UBS of ethynyl-estradiol + levonorgestrel, norethisterone, norethisterone + estradiol, levonorgestrel, medroxyprogesterone, male and female condoms, IUDs, and rapid pregnancy tests. The study considered the ...
Source: Cadernos de Saude Publica - July 7, 2021 Category: International Medicine & Public Health Authors: Ana Carolina Oliveira Ruivo Luiz Augusto Facchini Elaine Tomasi Louriele Soares Wachs Anaclaudia Gastal Fassa Source Type: research
